Journal article icon

Journal article

Donepezil for dementia due to Alzheimer's disease

Abstract:
Background Alzheimer's disease is the most common cause of dementia in older people. One approach to symptomatic treatment of Alzheimer's disease is to enhance cholinergic neurotransmission in the brain by blocking the action of the enzyme responsible for the breakdown of the neurotransmitter acetylcholine. This can be done by a group of drugs known as cholinesterase inhibitors. Donepezil is a cholinesterase inhibitor.

This review is an updated version of a review ... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's Version

Actions


Access Document


Files:
Publisher copy:
10.1002/14651858.cd001190.pub3

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS; CSM
Role:
Author
ORCID:
0000-0002-8310-9911
National Institute for Health Research More from this funder
University of Melbourne More from this funder
Barwon Health More from this funder
Publisher:
John Wiley and Sons, Ltd. Publisher's website
Journal:
Cochrane Database of Systematic Reviews Journal website
Volume:
6
Issue:
1
Pages:
Art. No.: CD001190
Publication date:
2018-06-18
DOI:
EISSN:
1469-493X
Pubs id:
pubs:859096
URN:
uri:04001ef3-178d-4243-a724-7e0d9f79247d
UUID:
uuid:04001ef3-178d-4243-a724-7e0d9f79247d
Local pid:
pubs:859096
Language:
English

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP